The Medicines Co.'s 3 Acute Care Drugs Approved in EU - Analyst Blog

A generic image of a calculator, a person holding a pen and papers laid out on a table.
Credit: Shutterstock photo

The Medicines CompanyMDCO announced that the European Commission (EC) has cleared three of the company's hospital acute care products - Kengrexal (cangrelor), Orbactiv (oritavancin) and Raplixa (sealant powder).

The approvals did not come as a surprise as earlier this year, the European Medicines Agency's Committee for Medicinal Products for Human Use had issued positive opinions regarding the marketing authorization for Orbactiv, Raplixa and Kengrexal.

Kengrexal is the first and only immediately bioavailable and quickly reversible intravenous small molecule antiplatelet agent to prevent platelet activation and aggregation that leads to thrombosis in the acute care setting, including in patients undergoing PCI. A new drug application for Kengreal is under FDA review.

Orbactiv, an intravenous antibiotic, will address acute bacterial skin and skin structure infections caused by susceptible isolates of Gram-positive microorganisms, including Methicillin-resistant Staphylococcus aureus. We note that Orbactiv is already approved in the U.S.

Raplixa is a ready-to-use, biologically active, powdered fibrin sealant that provides hemostasis in a wide range of bleeding settings. A biologics license application for Raplixa is under FDA review. The company expects this product to be well received by the surgical community.

We are pleased with the EC approval for Orbactiv, Raplixa and Kengrexal. We expect investor focus to remain on regulatory updates from the company.

The Medicines Co. carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Affymetrix Inc. AFFX , Cytokinetics, Incorporated CYTK and Lannett Company, Inc. LCI . All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDICINES CO (MDCO): Free Stock Analysis Report

AFFYMETRIX INC (AFFX): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More